Month: March 2021

Posted on

PHPUgly - 229: No Perceived Value

Links from the show:

This episode of PHPUgly was sponsored by:

PHPUgly streams the recording of this podcast live. Typically every Thursday night around 9 PM PT. Come and join us, and subscribe to our Youtube Channel, Twitch, or Periscope. Also, be sure to check out our Patreon Page.

Twitter Account https://twitter.com/phpugly

Host:

Streams:

Powered by Restream

Patreon Page

PHPUgly Anthem by Harry Mack / Harry Mack Youtube Channel

Posted on

Motley Fool Money - GameStop, Adobe, and Domino’s CEO Ritch Allison

GameStop’s volatility continues in the wake of earnings. Adobe has a strong start to the fiscal year. Restoration Hardware hits an all-time high. Laser equipment maker Coherent settles on a suitor. Darden Restaurants serves up a stronger-than-expected quarter. And Pepsi teams up with Peeps on a marshmallow-flavored cola. Motley Fool analysts Ron Gross and Jason Moser discuss those stories and share two stocks on their radar: Marvell Technology and Vulcan Materials. Plus, Domino’s CEO Ritch Allison talks about the rise of delivery services and the changing competitive landscape.

Looking for more investment ideas?  Get 50% off Stock Advisor by going to http://RadarStocks.fool.com.

 

Learn more about your ad choices. Visit megaphone.fm/adchoices

Posted on

Stuff They Don't Want You To Know - The Episode Where We Ruin Sunscreen

Since ancient times, human beings have known the sun can be dangerous. Too much exposure to its rays can burn and prematurely age the skin. In fact, the concept of sunscreen may be a non-human invention, as various types of animals coat themselves in protective layers of mud to stave off the at-times brutal effects of heat and sunshine. Fast forward to the modern era -- sunscreen is a huge industry, and people across the planet use it on a daily basis. The science seems sound. Unlike some skin care products, sunscreen actually works... however, it appears sunscreen may also have a dark side. Tune in to learn more.

Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

They don't want you to read our book.: https://static.macmillan.com/static/fib/stuff-you-should-read/

See omnystudio.com/listener for privacy information.

array(3) { [0]=> string(150) "https://www.omnycontent.com/d/programs/e73c998e-6e60-432f-8610-ae210140c5b1/2e824128-fbd5-4c9e-9a57-ae2f0056b0c4/image.jpg?t=1749831085&size=Large" [1]=> string(10) "image/jpeg" [2]=> int(0) }
Posted on

SCOTUScast - United States v. Cooley – Post-Argument SCOTUScast

On March 23, 2021 the Supreme Court heard oral argument in United States v. Cooley. The question before the court was the lower courts erred in suppressing evidence on the theory that a police officer of an Indian tribe lacked authority to temporarily detain and search the respondent, Joshua James Cooley, a non-Indian, on a public right-of-way within a reservation based on a potential violation of state or federal law.
Anthony Ferate, Of Counsel at Spencer Fane LLP, joins us today to discuss this case's oral argument.
Posted on

CBS News Roundup - World News Roundup: 03/26

At least two dozen tornadoes cause death and destruction in the South. New Georgia voting law angers Democrats. USC sex abuse settlement. CBS News Correspondent Steve Kathan has today's World News Roundup.

To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy

Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Posted on

The Intelligence from The Economist - Growth and stagnation: Bangladesh’s first 50 years

The country has empowered its women, established itself as a garment-industry powerhouse and vastly improved public health—but its politics remains troubled. The pandemic has not reduced average global happiness, but rather reshaped it: the old are more content and the young less so. And a look at the staggering costs of the Suez Canal blockage. For full access to print, digital and audio editions of The Economist, subscribe here www.economist.com/intelligenceoffer
Posted on

What Next - What Next | Daily News and Analysis – TBD | The AstraZeneca Saga

Back in April 2020, AstraZeneca was hailed as a frontrunner in the race to get an effective vaccine to market. A year later, after a series of trial pauses, communication blunders, and PR problems, the vaccine is on the cusp of FDA approval. 


By all accounts, the company succeeded in making a safe, effective vaccine. So why has there been so much confusion about its rollout?


Guest: 

 

Peter Aldhous, science reporter at Buzzfeed News


Host

Lizzie O’Leary

 

Hosted on Acast. See acast.com/privacy for more information.

Posted on

What Next - What Next: TBD | Tech, power, and the future – The AstraZeneca Saga

Back in April 2020, AstraZeneca was hailed as a frontrunner in the race to get an effective vaccine to market. A year later, after a series of trial pauses, communication blunders, and PR problems, the vaccine is on the cusp of FDA approval. 


By all accounts, the company succeeded in making a safe, effective vaccine. So why has there been so much confusion about its rollout?


Guest: 

 

Peter Aldhous, science reporter at Buzzfeed News


Host

Lizzie O’Leary

 

Hosted on Acast. See acast.com/privacy for more information.

Posted on

What Next | Daily News and Analysis - TBD | The AstraZeneca Saga

Back in April 2020, AstraZeneca was hailed as a frontrunner in the race to get an effective vaccine to market. A year later, after a series of trial pauses, communication blunders, and PR problems, the vaccine is on the cusp of FDA approval. 


By all accounts, the company succeeded in making a safe, effective vaccine. So why has there been so much confusion about its rollout?


Guest: 

 

Peter Aldhous, science reporter at Buzzfeed News


Host

Lizzie O’Leary

 

Learn more about your ad choices. Visit megaphone.fm/adchoices